Pfizer announces positive topline results from Phase 3 study of hemophilia A gene therapy candidate
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Subscribe To Our Newsletter & Stay Updated